BCRX
BioCryst Pharmaceuticals, Inc.
13.90
-
0.30
2.11%
5 x 13.90
7 x 13.91
bid
ask
03:02 PM
timesize
Bearish
29
Bullish
78
sentiment
13.78
day range
14.16
7.61
52 week range
19.99
Prev Close14.20
Open14.06
Low13.78
High14.16
Volume968.32K
Avg. Volume2.59M
Market Cap2.58B
Inst. Own83.13%
Beta2.08
Short Ratio13.33
Div & Yield0.00 /
EPS-1.07
P/E
1yr Target18.30
50day MA13.41
200day MA13.11
^DJI
Dow Jones Industrial Average
29291.60
03:01 PM
-
635.30
2.12%
^IXIC
NASDAQ Composite
10678.70
03:01 PM
-
394.60
3.56%
^GSPC
S&P 500
3642.69
03:01 PM
-
101.83
2.72%
AAPL
Apple Inc.
140.41
03:02 PM
6 x 140.40
18 x 140.41
-
5.03
3.46%
GOOG
Alphabet Inc.
99.96
03:02 PM
10 x 99.62
8 x 99.63
-
2.28
2.23%
AMZN
Amazon.com, Inc.
115.01
03:02 PM
4 x 115.00
3 x 115.02
-
5.29
4.40%
MSFT
Microsoft Corporation
234.96
03:02 PM
8 x 234.11
10 x 234.20
-
11.83
4.79%
BABA
Alibaba Group Holding Limited
80.97
03:02 PM
1 x 80.97
2 x 80.99
-
3.35
3.97%
NFLX
Netflix, Inc.
227.27
03:02 PM
10 x 226.58
10 x 226.70
-
12.75
5.31%
TSLA
Tesla, Inc.
224.05
03:02 PM
12 x 223.34
11 x 223.44
-
14.08
5.91%
NVDA
NVIDIA Corporation
121.63
03:02 PM
8 x 121.15
8 x 121.24
-
9.67
7.36%
AMD
Advanced Micro Devices, Inc.
58.96
03:02 PM
6 x 58.97
2 x 58.98
-
8.89
13.10%
MU
Micron Technology, Inc.
52.99
03:02 PM
9 x 52.92
13 x 52.92
-
1.51
2.77%
SPY
SPDR S&P 500 ETF Trust
363.06
03:02 PM
12 x 362.50
13 x 362.51
-
10.14
2.72%
TQQQ
ProShares UltraPro QQQ
19.62
03:02 PM
10 x 19.45
10 x 19.46
-
2.39
10.88%
BRK-A
Berkshire Hathaway Inc.
405900.00
03:01 PM
12 x 405030.00
9 x 405473.00
-
10400.00
2.50%
| Day Gain | ||
| Gain | ||
| Market Val | ||
| Costs | ||
| Cash | ||
| Portfolio | ||
| Realized | ||
| Dividend |
News
...
Profile
...
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Earning
...
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2022-11-02 | 2022-09 | -0.29 | N/A | N/A | N/A |
| 2022-08-04 | 2022-06 | -0.36 | -0.32 | 0.04 | 11.11% |
| 2022-05-05 | 2022-03 | -0.39 | -0.4 | -0.01 | -2.56% |
| 2022-02-23 | 2021-12 | -0.31 | -0.4 | -0.09 | -29.03% |
| 2021-11-03 | 2021-09 | -0.3 | -0.33 | -0.03 | -10.00% |
| 2021-08-05 | 2021-06 | -0.22 | -0.24 | -0.02 | -9.09% |
Upgrade / Downgrade
...
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2022-08-08 | Oppenheimer | Downgrade | Outperform | Perform |
| 2022-08-05 | Barclays | Upgrade | Equal-Weight | |
| 2022-08-05 | Oppenheimer | Downgrade | Outperform | Perform |
| 2022-08-05 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| 2022-04-18 | Barclays | Downgrade | Overweight | Equal-Weight |
| 2022-04-12 | RBC Capital | Upgrade | Sector Perform |
Insider Holder
...
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2022-06-06 | ABERCROMBIE GEORGE B | Director | 12.87K | Stock Award(Grant) |
| 2022-06-06 | ASELAGE STEPHEN J | Director | 46.59K | Stock Award(Grant) |
| 2022-06-06 | GALSON STEVEN K | Director | 12.87K | Stock Award(Grant) |
| 2022-08-30 | HEGGIE THERESA | Director | 30.63K | Stock Award(Grant) |
| 2022-06-06 | HUTSON NANCY J | Director | 77.94K | Stock Award(Grant) |
| 2022-08-30 | INGRAM ROBERT ALEXANDER | Director | 96.44K | Stock Award(Grant) |
Institution Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-06-29 | Blackrock Inc. | 13.99M | 198.62M | 7.52% |
| 2022-06-29 | Vanguard Group, Inc. (The) | 13.81M | 196.10M | 7.43% |
| 2022-06-29 | Baker Brothers Advisors, LLC | 12.71M | 180.49M | 6.84% |
| 2022-06-29 | State Street Corporation | 11.00M | 156.27M | 5.92% |
| 2022-06-29 | Avoro Capital Advisors LLC | 6.50M | 92.30M | 3.50% |
| 2022-06-29 | Pictet Asset Management SA | 6.05M | 85.87M | 3.25% |
Fund Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 6.96M | 98.89M | 3.75% |
| 2022-06-29 | Vanguard Total Stock Market Index Fund | 5.47M | 77.62M | 2.94% |
| 2022-08-30 | Fidelity Select Portfolios - Biotechnology | 4.35M | 61.73M | 2.34% |
| 2022-08-30 | iShares Russell 2000 ETF | 4.03M | 57.19M | 2.17% |
| 2022-06-29 | Vanguard Extended Market Index Fund | 2.56M | 36.41M | 1.38% |
| 2022-06-29 | Vanguard Small-Cap Index Fund | 2.33M | 33.03M | 1.25% |
Dividend
...
| Dividend | Date |
|---|---|
| 0 | 2014-06-11 |
| 0 | 2014-06-05 |
| 0 | 2014-05-20 |
| 0 | 2014-05-16 |
| 0 | 2014-04-02 |
This topic has been deleted. Only users with topic management privileges can see it.
-
$BCRX Where is he
-
$BCRX This is like having eye teeth pulled ouch ouch!
-
$BCRX What is this went to the kitchen for a beer and came back and we dropped all the way to 15.80
-
$BCRX I don’t think I can take 67 more of this
-
$BCRX The only thing to say here is THANK YOU FROM THE BOTTOM OF MY HEART MR. STONEHOUSE.
-
$BCRX @Beer Good switch to Blatz Beer it’s goood
-
$BCRX That’s OK you can go back to sleep we can try it again tomorrow when you’ve had a little more rest
-
$BCRX I know what it is it’s a short attack by those Gritonites led by you know who they have been planning this for several months
-
$BCRX What a way to throw away 5 30 packs of Keystone Light
-
$BCRX I guess taking profits is good but there is a much bigger pot of gold at the end of this Rainbow if u hold as the Village Idiot says “come on man”
-
$BCRX Ain’t it so “If your going through hell, keep on going” Winston Churchill
-
$BCRX Did our President say something stupid again?
-
$BCRX What government Larry ?
-
$BCRX We going home early today?
-
$BCRX Wait a minute I’ve got some powder let’s turn this ship around and head back north to that 12.50 heading
-
$BCRX Hate to say it out loud but I’m getting tired of these buying opportunities, how about you?
-
$BCRX 5 Shares at a whack is the game - - bastards
-
$BCRX Disgusting!
-
$BCRX I think I can I think I can
-
$BCRX I take that back but I still have a hard time finding Heavy Bud in Farmersville Tx
-
3 Biotech Stocks to Buy Now for Extraordinary Gains
investorplace.com • -
Options Bulls Blast Phama Stock on Lifted Clinical Hold
schaeffersresearch.com • -
3 Fast-Growing Stocks to Buy Now
fool.com • -
BioCryst to Report Second Quarter 2022 Financial Results on August 4
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
BioCryst: A Prudent Diversification
seekingalpha.com • -
7 Cheap Biotech Stocks to Buy Now
investorplace.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst to Report First Quarter 2022 Financial Results on May 5
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Falling
benzinga.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Plunging Today
benzinga.com • -
BioCryst Provides Tremendous Option Value
seekingalpha.com • -
BioCryst: Great Execution, Impressive Pipeline, Long Cash Runway
seekingalpha.com • -
7 Top Growth Stocks to Buy as We Step Into November
investorplace.com • -
BioCryst to Report Third Quarter 2021 Financial Results on November 3
globenewswire.com • -
7 Best Growth Stocks to Buy and Hold for the Next 10 Years
investorplace.com • -
2 Super-Charged Growth Stocks to Buy Now
fool.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
NICE Recommends BioCryst's Hereditary Angioedema Med
benzinga.com • -
What Wall Street Still Has Wrong. BioCryst To Become Next Rare Disease Giant
seekingalpha.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
BioCryst Appoints Dr. Steven Galson to Board of Directors
globenewswire.com • -
BioCryst Stock Jumps After Pulling Out $200M Equity Raise
benzinga.com • -
BioCryst Withdraws Public Offering
globenewswire.com • -
BioCryst Pharma Stock Heads Higher Thursday: Here's Why
benzinga.com • -
3 Biotech Stocks That Could Rocket Higher
fool.com • -
BioCryst to Report Second Quarter 2021 Financial Results on August 5
globenewswire.com • -
BioCryst Pharmaceuticals - Orladeyo Revenue Will Drive Share Price
seekingalpha.com • -
7 A-Rated Biotech Stocks to Buy Now
investorplace.com • -
BioCryst Pharmaceuticals: An Orphan Disease Innovator With More Upside
seekingalpha.com • -
Is BioCryst a Good Stock to Buy Now?
fool.com • -
BioCryst: Solid Delivery And Follow Through
seekingalpha.com • -
BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference
globenewswire.com • -
BCRX Stock Price: $15 Target By Piper Sandler
pulse2.com • -
BioCryst Technical Levels To Watch
benzinga.com •
